Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|July 2, 2015
- Pharmaceutical Technology-07-02-2015
- Volume 39
- Issue 7
Package Testing System Ensures Integrity
PTI Inspection System’s VeriPac 310 leak detection and package integrity testing system reduces waste and provides the user with a clear evaluation of package integrity.
PTI Inspection System’s VeriPac 310 leak detection and package integrity testing system reduces waste and provides the user with a clear evaluation of package integrity. The system can test in any sequence and can perform repeated tests on a single package. The system uses American Society for Testing and Materials vacuum decay leak test method F2338-09, measures seal integrity of the entire package, and can detect defects down to 20 microns.
The operator interface uses touch screen technology and has test parameter storage of up to 30 products. Up to 300 test results can be displayed on the touch screen with unlimited storage via electronic data and data transfer through Ethernet cable or SD card. The stainless steel instrument enclosure features tester dimensions of 12” W, 18.5” D, and 10” H.
PTI Inspection System
Articles in this issue
over 11 years ago
Ensuring Correct Tablet Countover 11 years ago
Testing the Stability of Biologicsover 11 years ago
Breakthrough Drugs Raise Development and Production Challengesover 11 years ago
Lack of Expertise Hinders Adoption of Continuous API Synthesisover 11 years ago
Unravelling the Complexity of EU’s ATMP Regulatory Frameworkover 11 years ago
Solving Poor Solubility to Unlock a Drug's Potentialover 11 years ago
Mission Possible: Targeting Drugs to the Colonover 11 years ago
Compliance with US and EU Internal Audit Requirementsover 11 years ago
A Risk-Based Approach to Data Integrityover 11 years ago
Industry Expert Q&A with Gerard CreanerRelated to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.